Physician profile
David E Scott
NPI 1265915136
$3,499.25
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,491 · 2022: $919 · 2023: $690 · 2024: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,669.01 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $516.42 | 2021-2024 | Xifaxan |
| Janssen Biotech, INC. | $290.77 | 2021-2024 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $155.15 | 2021-2022 | |
| Qol Medical, LLC | $144.08 | 2022-2023 | Sucraid |
| Janssen Scientific Affairs, LLC | $107.70 | 2021 | |
| Daiichi Sankyo INC. | $93.01 | 2021-2022 | |
| Genzyme Corporation | $74.93 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $74.53 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.26 | 2021-2022 | |
| Redhill Biopharma INC. | $62.51 | 2021-2023 | Talicia |
| Regeneron Healthcare Solutions, INC. | $46.86 | 2022-2024 | Dupixent |
| Mylan Institutional INC. | $37.57 | 2023 | Hulio |
| E.R. Squibb & Sons, L.L.C. | $32.70 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.14 | 2024 | Bylvay |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.77 | 2023 | Cyltezo |
| Sandoz INC. | $21.03 | 2024 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $19.37 | 2021 | |
| Intercept Pharmaceuticals, INC. | $15.70 | 2021 | |
| Braintree Laboratories, INC. | $15.30 | 2021 | |
| Merck Sharp & Dohme LLC | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.